{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:07:42Z","timestamp":1762340862444},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1097\/mlr.0000000000000486","type":"journal-article","created":{"date-parts":[[2016,1,14]],"date-time":"2016-01-14T04:35:01Z","timestamp":1452746101000},"page":"343-349","source":"Crossref","is-referenced-by-count":21,"title":["Estimating the Population Benefits and Costs of Rituximab Therapy in the United States from 1998 to 2013 Using Real-World Data"],"prefix":"10.1097","volume":"54","author":[{"given":"Mark D.","family":"Danese","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina M.","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle L.","family":"Gleeson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Halperin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra L.","family":"Skettino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Mikhael","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-2-20210211","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMhpr0807774","article-title":"Limits on Medicares ability to control rising spending on cancer drugs.","volume":"360","author":"Bach","year":"2009","journal-title":"N Engl J Med"},{"key":"R2-2-20210211","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1056\/NEJMsb1013826","article-title":"Bending the cost curve in cancer care.","volume":"364","author":"Smith","year":"2011","journal-title":"N Engl J Med"},{"key":"R3-2-20210211","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/jnci\/djq495","article-title":". Projections of the cost of cancer care in the United States: 2010-2020.","volume":"103","author":"Mariotto","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"R4-2-20210211","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-14-586","article-title":". Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis.","volume":"14","author":"Khor","year":"2014","journal-title":"BMC Cancer"},{"key":"R5-2-20210211","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.0887-378X.2004.00327.x","article-title":"Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages.","volume":"82","author":"Kravitz","year":"2004","journal-title":"Milbank Q"},{"key":"R7-2-20210211","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1053\/sonc.2002.30145","article-title":". Rituximab: ongoing and future clinical development.","volume":"29","author":"Grillo-Lopez","year":"2002","journal-title":"Semin Oncol"},{"key":"R8-2-20210211","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1634\/theoncologist.2010-0306","article-title":". US Food and Drug Administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia.","volume":"16","author":"Casak","year":"2011","journal-title":"Oncologist"},{"key":"R9-2-20210211","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":". CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"R10-2-20210211","first-page":"CD008079","article-title":". Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia.","volume":"11","author":"Bauer","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"R11-2-20210211","first-page":"CD003805","article-title":". Chemotherapy plus rituximab versus chemotherapy alone for B-cell non-Hodgkins lymphoma.","volume":"4","author":"Schulz","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"suppl IV","key":"R12-2-20210211","first-page":"3","article-title":". Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population.","volume":"40","author":"Warren","year":"2002","journal-title":"Med Care"},{"issue":"suppl IV","key":"R13-2-20210211","first-page":"55","article-title":". Utility of the SEER-Medicare data to identify chemotherapy use.","volume":"40","author":"Warren","year":"2002","journal-title":"Med Care"},{"key":"R16-2-20210211","doi-asserted-by":"crossref","first-page":"6079","DOI":"10.1002\/cncr.27638","article-title":". Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma.","volume":"118","author":"Griffiths","year":"2012","journal-title":"Cancer"},{"key":"R17-2-20210211","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/ajh.21878","article-title":". Survival in elderly follicular lymphoma patients who receive frontline chemo-immunotherapy.","volume":"85","author":"Griffiths","year":"2010","journal-title":"Am J Hematol"},{"key":"R18-2-20210211","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1182\/blood-2010-08-301929","article-title":". An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia.","volume":"117","author":"Danese","year":"2011","journal-title":"Blood"},{"key":"R19-2-20210211","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3109\/07357907.2011.616251","article-title":". Infused therapy and survival in older patients diagnosed with metastatic breast cancer who received trastuzumab.","volume":"29","author":"Griffiths","year":"2011","journal-title":"Cancer Invest"},{"key":"R20-2-20210211","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1186\/1471-2407-10-625","article-title":". Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL).","volume":"10","author":"Griffiths","year":"2010","journal-title":"BMC Cancer"},{"key":"R21-2-20210211","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/1536867X0900900206","article-title":"Further development of flexible parametric models for survival analysis.","volume":"9","author":"Lambert","year":"2009","journal-title":"Stata J"},{"key":"R22-2-20210211","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/sim.4274","article-title":"The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt.","volume":"30","author":"Royston","year":"2011","journal-title":"Stat Med"},{"key":"R24-2-20210211","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":". Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe dEtudes des Lymphomes de lAdulte.","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"key":"R25-2-20210211","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":". Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves.","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"R27-2-20210211","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/978391","article-title":". Impact on medical cost, cumulative survival, and cost-effectiveness of adding rituximab to first-line chemotherapy for follicular lymphoma in elderly patients: an observational cohort study based on SEER-Medicare.","volume":"2012","author":"Griffiths","year":"2012","journal-title":"J Cancer Epidemiol"},{"key":"R28-2-20210211","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1524-4733.2008.00401.x","article-title":"An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard.","volume":"12","author":"Lee","year":"2009","journal-title":"Value Health"},{"key":"R29-2-20210211","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood-2011-04-348367","article-title":". Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma.","volume":"118","author":"Griffiths","year":"2011","journal-title":"Blood"},{"key":"R30-2-20210211","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectivenessthe curious resilience of the 50,000-per-QALY threshold.","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"key":"R31-2-20210211","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/jnci\/djn383","article-title":". Estimates and projections of value of life lost from cancer deaths in the United States.","volume":"100","author":"Yabroff","year":"2008","journal-title":"J Natl Cancer Inst"}],"container-title":["Medical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MLR.0000000000000486","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:01:57Z","timestamp":1620961317000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005650-201604000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/mlr.0000000000000486","relation":{},"ISSN":["0025-7079"],"issn-type":[{"value":"0025-7079","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}